Search

Your search keyword '"NOGUCHI, CHISHIO"' showing total 15 results
Start Over Author "NOGUCHI, CHISHIO"
15 results on '"NOGUCHI, CHISHIO"'

4. Experience-Related Factors in the Success of Beginner Endoscopic Ultrasound-Guided Biliary Drainage: A Multicenter Study

Author

Sagami, Ryota, primary, Mizukami, Kazuhiro, additional, Okamoto, Kazuhisa, additional, Noguchi, Chishio, additional, Sato, Takao, additional, Nishikiori, Hidefumi, additional, Kawahara, Yoshinari, additional, Wada, Masahiro, additional, Otsuka, Yuichiro, additional, Fukuchi, Satoshi, additional, Takihara, Hiroshi, additional, Kuraoka, Naosuke, additional, Suzuki, Keita, additional, and Murakami, Kazunari, additional

Published
2023
Full Text
View/download PDF

6. ID: 3520660 RISK FACTORS AND PREVENTIVE MEASURES FOR POST-ERCP PANCREATITIS IN BILIARY ERCP: A MULTICENTER PROSPECTIVE COHORT STUDY IN JAPAN

Author

Asada, Masanori, primary, Fujita, Koichi, additional, Yazumi, Shujiro, additional, Kawamoto, Hirofumi, additional, Takenaka, Mamoru, additional, Maruo, Toru, additional, Matsumoto, Kazuya, additional, Matsumoto, Hisakazu, additional, Nebiki, Hiroko, additional, Kurita, Akira, additional, Onoyama, Takumi, additional, Tomoda, Takeshi, additional, Ueki, Toshiharu, additional, Hanada, Keiji, additional, Tsujimae, Masahiro, additional, Matsubara, Tokuhiro, additional, Yasumura, Satoki, additional, Okazaki, Akihito, additional, Hirao, Ken, additional, Tamura, Takashi, additional, Marui, Saiko, additional, Kamada, Hideki, additional, Hasegawa, Kazunori, additional, Noguchi, Chishio, additional, Mitoro, Akira, additional, Masuda, Atsuhiro, additional, Moriyama, Ichiro, additional, Takada, Ryoji, additional, Katayama, Toshiro, additional, and Kawamura, Takashi, additional

Published
2021
Full Text
View/download PDF

8. 1173 A MULTICENTER PROSPECTIVE COHORT STUDY OF ADVERSE EVENTS ASSOCIATED WITH BILIARY ERCP

Author

Fujita, Koichi, primary, Yazumi, Shujiro, additional, Kawamoto, Hirofumi, additional, Takenaka, Mamoru, additional, Maruo, Toru, additional, Matsumoto, Kazuya, additional, Matsumoto, Hisakazu, additional, Asada, Masanori, additional, Nebiki, Hiroko, additional, Kurita, Akira, additional, Onoyama, Takumi, additional, Tomoda, Takeshi, additional, Ueki, Toshiharu, additional, Hanada, Keiji, additional, Tsujimae, Masahiro, additional, Matsubara, Tokuhiro, additional, Yasumura, Satoki, additional, Okazaki, Akihito, additional, Hirao, Ken, additional, Tamura, Takashi, additional, Marui, Saiko, additional, Kamada, Hideki, additional, Hasegawa, Kazunori, additional, Noguchi, Chishio, additional, Mitoro, Akira, additional, Katayama, Toshiro, additional, and Kawamura, Takashi, additional

Published
2020
Full Text
View/download PDF

9. Endoscopic ultrasound-guided biliary drainage for malignant biliary obstruction with surgically altered anatomy: a multicenter prospective registration study

Author

Minaga, Kosuke, primary, Takenaka, Mamoru, additional, Ogura, Takeshi, additional, Tamura, Takashi, additional, Kuroda, Taira, additional, Kaku, Toyoma, additional, Uenoyama, Yoshito, additional, Noguchi, Chishio, additional, Nishikiori, Hidefumi, additional, Imai, Hajime, additional, Sagami, Ryota, additional, Fujimori, Nao, additional, Higuchi, Kazuhide, additional, Kudo, Masatoshi, additional, Chiba, Yasutaka, additional, and Kitano, Masayuki, additional

Published
2020
Full Text
View/download PDF

10. Endoscopic ultrasound-guided biliary drainage for malignant biliary obstruction with surgically altered anatomy: a multicenter prospective registration study.

Author

Minaga, Kosuke, Takenaka, Mamoru, Ogura, Takeshi, Tamura, Takashi, Kuroda, Taira, Kaku, Toyoma, Uenoyama, Yoshito, Noguchi, Chishio, Nishikiori, Hidefumi, Imai, Hajime, Sagami, Ryota, Fujimori, Nao, Higuchi, Kazuhide, Kudo, Masatoshi, Chiba, Yasutaka, and Kitano, Masayuki

Abstract

Background: Endoscopic treatment for malignant biliary obstruction (MBO) in patients bearing surgically altered anatomy (SAA) is not well-established. Although endoscopic ultrasound-guided biliary drainage (EUS-BD) has emerged as a new treatment option for MBO, limited data are available regarding the efficacy and safety of EUS-BD in patients with SAA. We conducted a multicenter prospective registration study to evaluate the efficacy and safety of EUS-BD in this population. Methods: This study involved 10 referral centers in Japan. Patients with SAA who were scheduled to receive EUS-BD for unresectable MBO between May 2016 and September 2018 were prospectively registered. The primary endpoint was technical success and the secondary outcomes were clinical success, procedure time, procedure-related adverse events (AEs), stent patency, and overall survival. Results: In total, 40 patients were prospectively enrolled. The surgical reconstruction methods were gastrectomy with Roux-en-Y reconstruction (47.5%), gastrectomy with Billroth-II reconstruction (15%), pancreaticoduodenectomy (27.5%), and hepaticojejunostomy with Roux-en-Y reconstruction (10%). EUS-BD was performed for primary biliary drainage in 31 patients and for rescue biliary drainage in nine patients. Transmural stenting alone (60%), antegrade stenting alone (5%), and a combination of the two techniques (35%) were selected for patients treated with EUS-BD. Technical and clinical success rates were 100% (95% confidence interval, 91.2–100.0%) and 95% (95% confidence interval, 83.1–99.4%), respectively. Mean procedure time was 36.5 min. Early AEs were noted in six patients (15%): three self-limited bile leak, one bile peritonitis, and two pneumoperitonea. Late AEs occurred in six patients (15%): one jejunal ulcer and five stent occlusions. Stent patency rate after 3 months of survival was 95.7% (22/23). Median overall survival was 96 days. Conclusion: EUS-BD for MBO in patients with SAA appears to be effective and safe not only as a rescue drainage technique after failed endoscopic retrograde cholangiography but also as a primary drainage technique. Clinical Trial Registration: UMIN000022101 [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

12. 107 UNCOVERED VERSUS COVERED SELF-EXPANDABLE METAL STENTS IN PALLIATIVE ENDOSCOPIC TREATMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A LARGE MULTICENTER RANDOMIZED TRIAL IN WEST JAPAN

Author

Kitano, Masayuki, primary, Chiba, Yasutaka, additional, Yamao, Kentaro, additional, Ogura, Takeshi, additional, Eguchi, Takaaki, additional, Moriyama, Ichiro, additional, Yamashita, Yukitaka, additional, Kato, Hironari, additional, Kayahara, Takahisa, additional, Hoki, Noriyuki, additional, Okabe, Yoshinobu, additional, Shiomi, Hideyuki, additional, Nakai, Yoshitaka, additional, Kushiyama, Yoshinori, additional, Fujimoto, Yoshifumi, additional, Hayashi, Shiro, additional, Bamba, Shigeki, additional, Kudo, Yasushi, additional, Azemoto, Nobuaki, additional, Ueki, Toshiharu, additional, Kodama, Yuzo, additional, Asada, Masanori, additional, Matsumoto, Kazuya, additional, Nebiki, Hiroko, additional, Takihara, Hiroshi, additional, Noguchi, Chishio, additional, Kamada, Hideki, additional, Nakase, Kojiro, additional, Goto, Daisuke, additional, Sanuki, Tsuyoshi, additional, Koga, Tetsuya, additional, and Kawamoto, Hirofumi, additional

Published
2018
Full Text
View/download PDF

13. 1038 A MULTICENTER PROSPECTIVE STUDY OF EUS-GUIDED HEPATICOGASTROSTOMY COMBINED WITH ANTEGRADE STENT PLACEMENT

Author

Ogura, Takeshi, primary, Kitano, Masayuki, additional, Takenaka, Mamoru, additional, Minaga, Kosuke, additional, Yamao, Kentaro, additional, Yamashita, Yukitaka, additional, Hatamaru, Keiichi, additional, Noguchi, Chishio, additional, Kuroda, Taira, additional, Nishikiori, Hidefumi, additional, Higuchi, Kazuhide, additional, and Chiba, Yasutaka, additional

Published
2018
Full Text
View/download PDF

14. Multicenter prospective evaluation study of endoscopic ultrasound‐guided hepaticogastrostomy combined with antegrade stenting (with video)

Author

Ogura, Takeshi, primary, Kitano, Masayuki, additional, Takenaka, Mamoru, additional, Okuda, Atsushi, additional, Minaga, Kosuke, additional, Yamao, Kentaro, additional, Yamashita, Yukitaka, additional, Hatamaru, Keiichi, additional, Noguchi, Chishio, additional, Gotoh, Yasuhiko, additional, Kuroda, Taira, additional, Yokota, Tomoyuki, additional, Nishikiori, Hidefumi, additional, Sagami, Ryota, additional, Higuchi, Kazuhide, additional, and Chiba, Yasutaka, additional

Published
2017
Full Text
View/download PDF

15. The Differential Effects of Angiotensin II Type 1 Receptor Blockers on Microalbuminuria in Relation to Low-Grade Inflammation in Metabolic Hypertensive Patients

Author

Yano, Yuichiro, Hoshide, Satoshi, Ishikawa, Joji, Noguchi, Chishio, Tukui, Daisuke, Takanori, Hidaka, Tada, Masashi, Kanemaru, Yoshimasa, Yano, Ayako, Ishikawa, Shizukiyo, Shimada, Kazuyuki, and Kario, Kazuomi

Subjects
ANGIOTENSIN II, GLUCOSE, HYPERTENSION, PATIENTS, C-reactive protein
Abstract

Background: A dual angiotensin type 1 receptor blocker (ARB)/peroxisome proliferator-activated receptor-γ (PPARγ) agonist telmisartan may be more useful for microalbuminuria reduction than ARBs with no PPARγ agonistic action. We investigated whether there is a difference between the effects of telmisartan and valsartan with respect to microalbuminuria reduction, and the association with improvement of metabolic features or suppression of the inflammatory state. Methods: Fifty-three patients who had metabolic syndrome and had been taking valsartan were recruited. All of these patients were randomly assigned to replace valsartan by telmisartan (telmisartan group; n = 30) or to keep taking valsartan (control group; n = 21). Various parameters were measured at baseline and 12 weeks after randomization. Results: There were no significant changes in blood pressure (BP), glucose, and lipid parameters between baseline and 12 weeks after randomization in either group. There was a significant increase in high molecular weight adiponectin in the telmisartan group (4.6 v 5.0 μg/mL, P = .024), whereas there was no significant change in the control group. The reductions of microalbuminuria and high-sensitivity C-reactive protein (hs-CRP) were significant in the telmisartan group (28.1 v 18.9 mg/g·Cr and 0.77 v 0.60 mg/L, respectively, P = .001 and P = .022), whereas there was no significant change in the control group. The reductions of microalbuminuria and hs-CRP were significantly correlated with each other (γ = 0.413, P = .003). Conclusions: The dual ARB/PPARγ agonist telmisartan achieved more microalbuminuria reduction than an ARB with no PPARγ agonistic action, possibly through suppression of the inflammatory state in metabolic hypertensive patients. [Copyright &y& Elsevier]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results